Clinical Trial Update: Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of regorafenib plus gemcitabine in metastatic pancreatic cancer (metastatic pancreatic adenocarcinoma) has been terminated with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Regorafenib (regorafenib)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Metastatic Pancreatic Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-10